# GPT-5.2 Review

**Role:** External referee review
**Model:** openai/gpt-5.2
**Paper:** paper.pdf
**Timestamp:** 2026-02-17T17:30:48.975706
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 18425 in / 4716 out
**Response SHA256:** 381b59cfbaa7acc5

---

## Referee Report: “Paying More, Getting Less? The Perverse Effects of Medicaid HCBS Reimbursement Rate Increases on Provider Supply”

### Summary / contribution
The paper uses newly released T‑MSIS provider spending data (state×month panels constructed from NPI-linked claims) to study whether large Medicaid HCBS personal care reimbursement increases expand provider supply. Treatment is defined as a sustained ≥15% jump in average payment per claim for personal care codes, yielding 23 treated states with staggered timing (2018–2023) and 29 never-treated controls. The author estimates TWFE and modern staggered DiD (Callaway & Sant’Anna; plus Sun & Abraham in appendix) and finds economically meaningful but statistically imprecise *non-positive* effects on provider counts and utilization. Placebos on E/M office visits are null. Heterogeneity suggests declines among individual (Type 1) providers.

The topic is important for health policy and public finance, and the data are potentially a major advance. The paper is promising, but for a top general-interest journal it needs substantially stronger identification and measurement validation—especially because treatment is *constructed from the same data* as outcomes and because “average payment per claim” is a noisy proxy for a fee schedule rate in a setting with heterogeneous units (15-min vs per diem), case mix shifts, and managed care encounter pricing.

Below I separate *fatal / near-fatal* issues from *fixable* ones and propose concrete paths to strengthen the paper.

---

# 1. FORMAT CHECK

### Length
- Appears to be roughly **30–40 pages** of main text in 12pt, 1.5 spacing, plus appendices (hard to be exact from LaTeX source). **Pass** the “≥25 pages” criterion.

### References / coverage
- The paper cites some key DiD method papers (Callaway & Sant’Anna; Goodman-Bacon; de Chaisemartin & D’Haultfœuille; Sun & Abraham).
- **But the bibliography file isn’t shown** (only `\bibliography{references}`), so I cannot verify breadth. In-text citations suggest partial coverage, but the *policy and HCBS-specific* empirical literature is thin relative to what a top journal would expect (see Section 4 below for missing references).

### Prose vs bullets
- Introduction, background, conceptual framework, results, discussion are mostly paragraphs.
- However, **Institutional Background** includes a bullet list about ARPA heterogeneity; **Discussion/Implications** has a bulleted list of policy implications. This is acceptable (not a “FAIL”) since bullets are not dominating major sections, but for a top journal you may want to convert the most important lists into narrative paragraphs.

### Section depth
- Most major sections have ≥3 substantive paragraphs. **Pass**.

### Figures
- Figures are included via `\includegraphics{...}`; I can’t see them in source. I **do not flag** figure quality; this requires rendered PDF review.

### Tables
- Tables contain real numbers, not placeholders. **Pass**.

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

### (a) Standard errors reported
- Main tables report SEs in parentheses (Table 2 main TWFE; CS-DiD table; robustness table). **Pass**.

### (b) Significance testing / inference
- p-values are sometimes reported in text; clustered SEs used; randomization inference used. **Pass**, with caveats below.

### (c) 95% confidence intervals
- 95% CI is provided for TWFE main results in text (Section 6.1). Not consistently shown elsewhere (CS-DiD table, heterogeneity, robustness). **Mostly pass**, but I recommend reporting 95% CIs systematically for headline estimates (TWFE, CS-DiD, key heterogeneity).

### (d) Sample sizes (N)
- Tables report Observations (=4,161) for main regressions; placebo panel has different N but is not always shown in the placebo table. **Partial pass**: ensure every regression table/panel reports N (including heterogeneity and placebo outcomes).

### (e) DiD with staggered adoption
- The paper **explicitly acknowledges TWFE bias** and uses **Callaway & Sant’Anna with never-treated controls**; also mentions Sun-Abraham. **Pass** on modern staggered DiD requirements.

**However**: You still need to address two methodological vulnerabilities that are not resolved by CS-DiD:
1. **Treatment is measured endogenously from outcomes-adjacent data** (payment/claim) and may reflect compositional shifts rather than policy (see Section 3). Modern DiD doesn’t fix this.
2. **Inference with only ~52 clusters** (states/territories) and heavy serial correlation can make conventional cluster-robust SEs unreliable. Consider wild cluster bootstrap (Cameron, Gelbach & Miller) and/or randomization inference aligned with your assignment mechanism.

### (f) RDD
- Not applicable.

**Bottom line on methodology:** You meet the “minimum inference” bar. The real issue is not missing SEs; it is whether the *object being estimated* is well-defined (rate changes vs composition/measurement) and whether inference and assignment are aligned with the policy process.

---

# 3. IDENTIFICATION STRATEGY

## 3.1 What is the estimand?
The paper claims to estimate the causal effect of “reimbursement rate increases” on provider supply, but the treatment is operationalized as a ≥15% sustained jump in **average payment per claim** for a bundle of personal care HCPCS codes.

This creates ambiguity: are you estimating the effect of (i) fee schedule/unit reimbursement changes, (ii) shifts in billing units (15-min vs per diem), (iii) changes in authorized hours/intensity per beneficiary, (iv) managed care encounter pricing changes, (v) changes in the mix of codes (T1019 vs T1020), or (vi) auditing/claims-processing changes? Different mechanisms imply different expected relationships to NPI counts, and several can mechanically correlate with provider counts (e.g., suppression or billing patterns).

**This is currently the central identification weakness.**

## 3.2 Parallel trends / pre-trends
- You present CS-DiD event studies and claim flat pre-trends. That is helpful and necessary.
- But given the policy story (“states raise rates when shortages worsen”), **flat pre-trends over 6 quarters may not be sufficient**, especially when some cohorts are treated early (2018–2020) and the market is disrupted by COVID and post-2021 labor market changes. Slow-moving differential trends (multi-year) could remain.

**Suggested fixes**
1. Show **longer pre-trend windows** where feasible (e.g., 12–16 quarters for cohorts treated later), and present **formal pre-trend joint tests** (already possible in CS-DiD).
2. Add **state-specific linear trends** as a sensitivity check (not as preferred spec, but as a bounding exercise).
3. Consider a **stacked DiD / cohort-specific** approach (e.g., “stacked” event studies restricting controls to not-yet-treated + never-treated in a window) to show robustness of dynamics.

## 3.3 Exogeneity of timing (ARPA narrative)
- The institutional narrative that ARPA created an exogenous funding shock is plausible for post-2021 cohorts, but you also have multiple **pre-ARPA treatments (2018–2020)**.
- Pooling early and late cohorts weakens the ARPA exogeneity argument. A top journal will ask: *what identifies early treated states?* Are those policy changes plausibly exogenous?

**Suggested fixes**
- Separate analyses:
  - **ARPA-era sample**: restrict to cohorts treated after April 2021 (or after 2021Q2) and compare to never-treated.
  - **Pre-ARPA sample**: analyze 2018–2020 treatments with a different institutional justification (or treat them as a separate “historical” replication).
- Alternatively, use ARPA as an instrument-like shock: e.g., estimate effects using only **ARPA-induced rate increases validated by CMS spending plans** (see below).

## 3.4 Placebos
- E/M office visit placebo is good and well-motivated.
- However, E/M is in a very different market (physician services) and may not share confounders relevant to personal care supply (e.g., low-wage labor market conditions, COVID exposure, long-term care policy changes).

**Suggested placebos (stronger)**
- Within HCBS / similar labor market: choose codes for services delivered by similar paraprofessional workforce but *not targeted* by personal care rate changes (if any exist) or services in the same sector whose rates did not change.
- Use **“fake treatment dates”** within treated states (lead-shift) and report distribution of placebo ATTs.

## 3.5 Randomization inference
- Randomization inference is a nice addition, but it must match a plausible assignment mechanism. Randomly drawing 23 states and random dates from the observed distribution may not correspond to how policy is adopted (timing correlated with ARPA admin capacity; size correlated with baseline rates; etc.). Also RI seems applied to TWFE coefficient, which is not your preferred estimator.

**Suggested fix**
- Implement RI (or permutation inference) for the **CS-DiD aggregated ATT**, and constrain permutations to preserve salient features:
  - Keep the same number treated and the same cohort sizes.
  - Restrict treatment dates to feasible windows (e.g., post-ARPA for ARPA analysis).
  - Possibly permute within strata (e.g., by baseline rate quartile, Medicaid managed care penetration, region).

---

# 4. LITERATURE (missing references + BibTeX)

## 4.1 DiD / event-study methods (should be cited explicitly)
You cite several, but for a top journal, I recommend ensuring the following are included and discussed where relevant (especially for inference/event studies):

```bibtex
@article{BorusyakJaravelSpiess2021,
  author = {Borusyak, Kirill and Jaravel, Xavier and Spiess, Jann},
  title = {Revisiting Event Study Designs: Robust and Efficient Estimation},
  journal = {Working Paper},
  year = {2021}
}
@article{RothSantAnna2023,
  author = {Roth, Jonathan and Sant'Anna, Pedro H. C.},
  title = {When Is Parallel Trends Sensitive to Functional Form?},
  journal = {Econometrica},
  year = {2023},
  volume = {91},
  number = {2},
  pages = {737--747}
}
@article{CameronGelbachMiller2008,
  author = {Cameron, A. Colin and Gelbach, Jonah B. and Miller, Douglas L.},
  title = {Bootstrap-Based Improvements for Inference with Clustered Errors},
  journal = {The Review of Economics and Statistics},
  year = {2008},
  volume = {90},
  number = {3},
  pages = {414--427}
}
```

(If you prefer only published references, keep Borusyak et al. as NBER/CEPR working paper version if available.)

## 4.2 Medicaid physician participation / payment literature (deepen, but keep focused)
You cite Zuckerman and Decker; consider adding the ACA “fee bump” literature to benchmark why HCBS differs:

```bibtex
@article{PolskyEtAl2015,
  author = {Polsky, Daniel and Candon, Molly and Saloner, Brendan and Wissoker, David and Hempstead, Katherine and Kenney, Genevieve M. and Rhodes, Karin and Kleiner, Samuel and et al.},
  title = {Changes in Primary Care Access Between 2012 and 2014 for New Patients With Medicaid and Private Insurance},
  journal = {JAMA},
  year = {2015},
  volume = {314},
  number = {19},
  pages = {2013--2021}
}
@article{DeckerLiptonSommers2015,
  author = {Decker, Sandra L. and Lipton, Brandy J. and Sommers, Benjamin D.},
  title = {Medicaid Payment Levels to Physicians and the Affordable Care Act},
  journal = {JAMA},
  year = {2015},
  volume = {313},
  number = {4},
  pages = {356--358}
}
```

(Exact author lists/pages should be verified—please adjust BibTeX to the precise citation you use.)

## 4.3 HCBS / direct care workforce and reimbursement (missing and important)
A top policy journal will expect engagement with the direct care workforce literature and prior policy evaluations of wage floors / pass-through policies (common in Medicaid nursing home and HCBS contexts). Examples:

```bibtex
@article{Howes2005,
  author = {Howes, Candace},
  title = {Living Wages and Retention of Homecare Workers in San Francisco},
  journal = {Industrial Relations},
  year = {2005},
  volume = {44},
  number = {1},
  pages = {139--163}
}
@article{BaughmanSmith2008,
  author = {Baughman, Reagan A. and Smith, Kristin E.},
  title = {Labor Mobility of the Direct Care Workforce: Implications for the Provision of Long-Term Care},
  journal = {Health Economics},
  year = {2008},
  volume = {17},
  number = {8},
  pages = {965--980}
}
@article{FengEtAl2010,
  author = {Feng, Zhanlian and Grabowski, David C. and Intrator, Orna and Zinn, Jacqueline and Mor, Vincent},
  title = {Effect of State Medicaid Case-Mix Payment on Nursing Home Staffing},
  journal = {Health Services Research},
  year = {2010},
  volume = {45},
  number = {1},
  pages = {123--141}
}
```

Even if some are nursing-home focused, they are directly relevant because they study reimbursement and staffing/provider behavior in Medicaid-financed long-term care—your closest cousin market.

## 4.4 T-MSIS data validity / Medicaid administrative data
Given your “first to use” claim, you should engage with existing work describing and validating T‑MSIS (often emphasizing data quality limitations, state reporting heterogeneity):

```bibtex
@article{MACPAC2021TMSIS,
  author = {{Medicaid and CHIP Payment and Access Commission}},
  title = {T-MSIS Data Quality and Priorities for Improvement},
  journal = {Report to Congress / Issue Brief},
  year = {2021}
}
```

(Replace with the exact MACPAC/CMS documentation you rely on; there are multiple relevant reports/briefs.)

**Why these matter:** Without a careful T‑MSIS data quality discussion, reviewers will worry your “rate jumps” are artifacts of reporting changes rather than policy.

---

# 5. WRITING QUALITY (CRITICAL)

## Prose vs bullets
- Overall readable and in paragraphs. Bullets are used sparingly. **Pass**.

## Narrative flow / framing
- Strong hook (waiting lists; workforce crisis; ARPA funding).
- The contribution is stated clearly.
- One concern: the paper sometimes over-claims “first causal evidence” / “universe of billing records” without sufficiently qualifying limitations (state assignment via NPPES practice state; suppression; managed care encounter pricing). Tightening these claims will improve credibility.

## Sentence quality / accessibility
- Generally clear and accessible to non-specialists, with helpful institutional details.
- A few places could be sharpened to avoid internal tension:
  - The abstract says “no evidence” and “point estimates negative,” but also emphasizes RI p=0.024—readers may interpret that as evidence of a negative effect. You should reconcile: are you claiming “null” or “negative”? (This is not just prose; it’s inference coherence.)

## Tables
- Tables are mostly self-contained.
- Improvements needed for top journal standards:
  - Add **N states/clusters** explicitly in main tables.
  - For CS-DiD: report **95% CIs** and describe how SEs are computed (bootstrap? asymptotic? clustered?).
  - Robustness table mixes many estimands (TWFE coefficients, RI p-values, continuous dose). Consider splitting into multiple tables or panels with consistent columns, and always report N.

---

# 6. CONSTRUCTIVE SUGGESTIONS (to make the paper publishable in a top journal)

## 6.1 Validate the treatment: link “payment per claim” jumps to actual policy
This is the single most important revision.

Concrete steps:
1. **External crosswalk**: For each treated state (or at least a large subset), collect fee schedule documents / waiver amendments / ARPA spending plan details and show:
   - Effective dates of rate changes for T1019/S5125/etc.
   - Magnitude (per 15-min unit, per diem).
   - Whether change was permanent vs temporary add-on.
2. Show a table: *Policy effective date vs detected date*, and quantify alignment (mean absolute difference in months; share within ±1 month).
3. If many detected jumps do not correspond to policy, refine the algorithm:
   - Work at the **code level** (T1019 separately from T1020) rather than averaging across heterogeneous units.
   - Use **median paid per unit** or a within-code paid/claim ratio to reduce composition bias.
   - Consider measuring “rate” as paid per *15-minute unit* where feasible (if units exist—if not, state clearly).

Outcome: you can credibly claim you are estimating the effect of *reimbursement policy*, not billing composition.

## 6.2 Use outcomes that better approximate “workforce supply”
NPI counts are a noisy proxy for worker counts, especially if agencies consolidate billing.

Possible improvements:
- Distinguish:
  - **Active individual NPIs** (Type 1) as closer to workers.
  - For Type 2, measure **number of servicing NPIs** if available (your schema includes billing×servicing provider). If servicing NPIs represent individual aides, that could be a major improvement.
- Analyze **total hours/units** if a unit measure exists; if not, consider claims standardized by code and unit.
- If you cannot measure workers, lean into the paper’s actual contribution: “provider *billing entity* participation” and “billed service volume,” and be cautious interpreting as labor supply.

## 6.3 Clarify the estimand: effect of “rate increase” vs “spending shock”
Because ARPA increased FMAP and required reinvestment, states may have implemented multiple simultaneous changes (workforce programs, bonuses, admin expansions). Your “treatment” could proxy for a broader ARPA implementation intensity.

Suggested analyses:
- Add controls (or stratification) for other ARPA spending categories if you can code them from CMS plans.
- A “triple-diff” style approach: compare personal care vs another HCBS category within state over time, interacting with rate changes (requires credible unaffected comparison category).

## 6.4 Reconcile asymptotic SEs vs randomization inference
Right now, the paper simultaneously claims “precisely estimated null” and highlights RI p=0.024 for a negative effect. That will confuse referees.

Suggested resolution:
- Decide which inference framework is primary and why.
- If you keep RI, apply it to the **preferred CS-DiD ATT**, and explain the assignment mechanism.
- Add **wild cluster bootstrap p-values** for the main TWFE and key heterogeneity results (given ~52 clusters).

## 6.5 Heterogeneity and mechanisms: make “consolidation” testable
If consolidation is the story, test predictions:
- Does the **share of Type 2 billing** increase post-treatment?
- Do **average claims per provider** or **paid per provider** rise post-treatment (intensive margin), especially for organizations?
- Are exits concentrated among small-volume individual NPIs?
- If you can observe billing vs servicing NPIs, test whether billing consolidates while servicing remains stable.

## 6.6 Tighten the “first” claims and data limitations
Top journals will penalize overstatements. I recommend:
- Replace “universe of provider billing records” with “near-universe of observed billing records subject to suppression and state reporting differences.”
- Be explicit about what “52 states” means (50 states + DC + territories; but summary table says 50 states).

---

# 7. OVERALL ASSESSMENT

## Strengths
1. **Important policy question** with first-order fiscal stakes (ARPA HCBS spending; workforce shortages).
2. **New, potentially transformative data** (T‑MSIS provider spending) assembled into a usable panel.
3. Uses **modern staggered DiD estimators** (CS-DiD; Sun-Abraham) and provides event studies and placebo outcomes.
4. Clear writing and strong motivation; results are presented transparently (including nulls).

## Critical weaknesses (must address)
1. **Treatment validity / measurement**: “rate increases” inferred from average paid/claim may reflect composition, coding, encounter pricing, or reporting changes; without external validation the identification is not yet convincing for a top journal.
2. **Exogeneity of timing**: ARPA story does not cover pre-ARPA treated cohorts; pooling cohorts risks endogeneity (“rates raised when supply falls”), consistent with your own negative dose-response.
3. **Inference coherence**: tension between “null” and RI suggesting “significant negative”; also need stronger small-cluster inference.

## Specific high-priority revisions
- External policy validation and/or refined rate measurement at code/unit level.
- Separate ARPA-era analysis (post-2021) from earlier adoptions.
- Mechanism tests for consolidation using billing vs servicing NPIs (if feasible).
- Wild cluster bootstrap and RI aligned with CS-DiD.

Given the promise of the data and question, I view this as **salvageable with substantial revision**, but not yet at the publishable standard for AER/QJE/JPE/ReStud/Ecta/AEJ:EP.

DECISION: MAJOR REVISION